Showing results (1931-1940 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|September 23, 2017
Metformin as a repurposed therapy in advanced non-small cell lung cancer (NSCLC): results of a phase II trialAnish B Parikh, Peter Kozuch, Nicholas Rohs, et al.
Investigational New Drugs|September 23, 2017
Treatment-related serious adverse events and fatal adverse events with regorafenib in cancer patients: a meta-analysis of phase 3 randomized controlled trialsMeihui Cao, Feifei Li, Yue Wang, et al.
Investigational New Drugs|August 5, 2017
Synthesis, characterization, and evaluation of Cd[L-proline]2, a novel histone deacetylase inhibitor that induces epigenetic modification of histone deacetylase isoforms in A549 cellsAnusha Chidambaram, Arunachalam Sekar, Kavya S H, et al.
Investigational New Drugs|August 8, 2017
Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testingKyoungmin Lee, Changhoon Yoo, Kyu-Pyo Kim, et al.
Investigational New Drugs|August 31, 2017
Vinblastine and antihelmintic mebendazole potentiate temozolomide in resistant gliomasFranciele Cristina Kipper, Andrew Oliveira Silva, André Luis Marc, et al.
Investigational New Drugs|September 12, 2017
Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatmentSadahisa Ogasawara, Tetsuhiro Chiba, Yoshihiko Ooka, et al.
Investigational New Drugs|May 11, 2016
Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancerJoseph Kattan, Marwan Bachour, Fadi Farhat, et al.
Investigational New Drugs|February 18, 2016
The novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX-15Paula Kinsella, Lisa M Greene, Sandra A Bright, et al.
Investigational New Drugs|December 2, 2015
A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumorsManik Amin, Susan E Minton, Patricia M LoRusso, et al.
Investigational New Drugs|December 16, 2015
A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancerDustin A Deming, Ludmila L Cavalcante, Sam J Lubner, et al.
Pageof 372